Summary: A new study has demonstrated that a brain-selective estrogen prodrug can mitigate the severe cognitive and physiological side effects of anti-estrogen breast cancer therapies. The research evaluated 10ฮฒ,17ฮฒ-dihydroxyestra-1,4-dien-3-one (DHED), a compound designed to deliver estrogen exclusively to the cerebral cortex while bypassing peripheral tissues.
Utilizing an advanced aged-marmoset model, investigators discovered that DHED successfully elevates brain estrogen levels, reverses therapy-induced neural degradation, and significantly improves both memory and sleep architecture.
Key Facts
- The Treatment Adherence Barrier: The vast majority of breast cancers are driven and exacerbated by estrogens, leading clinicians to prescribe aromatase inhibitors like letrozole to block estrogen production and prevent tumor recurrence. However, the resulting systemic estrogen depletion causes severe side effects that frequently lead patients to discontinue the life-saving treatment.
- Brain-Targeted Delivery: DHED acts as a localized delivery mechanism, supplying protective estrogen strictly to the brain without reintroducing the hormone to the rest of the body, where it could trigger cancer recurrence.
- Advancing to Non-Human Primates: Moving past initial rodent assays, a research team led by Dr. Agnรจs Lacreuse validated the compound’s efficacy in aged marmosets, offering a more anatomically accurate translational model for human menopause and aging.
- Neural and Cognitive Rescue: In marmosets concurrently treated with the inhibitor letrozole, the administration of DHED successfully increased brain-specific estrogen levels, restored memory performance, and improved sleep quality. It also directly reversed adverse structural neural changes induced by the cancer medication.
- Sex-Specific Thermoregulation Divergence: The study unmasked an unexpected variable: DHED exerted disparate effects on body temperature regulation between males and females, signaling a critical need to adjust dosing strategies in future research.
- Broad Menopausal Applications: Beyond its primary design as a hormonal shield for breast cancer patients, lead investigator Lacreuse notes that DHED holds significant therapeutic promise for alleviate standard menopausal symptoms in the general population.
Source: SfN
Most breast cancers are worsened by estrogens.ย To combat the recurrence ofย these cancers, clinicians treat patients with inhibitorsย for estrogen production, like letrozole.ย Butย many patientsย doย notย adhere to thisย treatmentย due toย negativeย side effects.ย
reclinical work in rodentsย suggests thatย a drug calledย 10ฮฒ,17ฮฒ-dihydroxyestra-1,4-dien-3-oneย (DHED), whichย delivers estrogen only toย the brain,ย may beย an effective, safeย way to reduceย theseย side effects.
New inย Journal of Neuroscience, researchers led by Agnรจs Lacreuse, fromย theย University of Massachusetts Amherst,ย exploredย howย DHEDย works inย a more advanced animal model than rodents: aged marmosets.ย
Following treatments with letrozole, the research team discovered that treating marmosets with DHED increased estrogen specifically in the brain and improved both memory and sleep. DHED also reversed neural changes from letrozole. DHED had different effects on body temperature regulation in males and females, pointing to the need for more research in this area.
Says Lacreuse, โOur workย suggestsย that DHED is a promising new hormonal therapy for women with breast cancer and perhaps all menopausal women.โย
The researchers plan to explore the mechanisms DHED acts through in the brain and to assess whether differentย drugย doses improve temperature regulation issuesย from treatment.ย
Key Questions Answered:
A: Because the side effects of systemic estrogen depletion are incredibly harsh. Drugs like letrozole save lives by cutting off estrogen production to starve the cancer, but starving the brain of estrogen causes severe memory problems, insomnia, and hot flashes, leading many patients to abandon treatment.
A: Through absolute target precision. DHED is engineered as a brain-selective drug, meaning it enters and delivers estrogen only to cerebral tissues where it rescues memory and sleep, while completely avoiding peripheral body tissues where it could otherwise fuel tumor growth.
A: The use of an advanced primate model. The UMass Amherst team tested DHED on aged marmosets, whose complex brains and aging profiles mimic human neurology and menopause far more accurately than mice, proving that DHED effectively repairs medication-induced brain changes in primates.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuropharmacology and cancer research news
Author:ย SfN Media
Source:ย SfN
Contact:ย SfN Media โ SfN
Image:ย The image is credited to Neuroscience News
Original Research:ย Open access.
โBrain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behaviorโ by Hannah Cournoyer, Abigail Monroy Duenas, Anusha Bharadwaj, Nicholas Kania, Iris Burns, Kasey Regan, Jacob Sweet, Jordan Amato, Chloe Saia, Gabrielle Sabbouh, Joseph Bergman, Vien Nguyen, Luke Remage-Healey, Elena M. Vazey, Istvan Merchenthaler, Laszlo Prokai and Agnรจs Lacreuse.ย Journal of Neuroscience
DOI:10.1523/JNEUROSCI.2021-25.2026
Abstract
Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior
Blocking estrogen synthesis via aromatase inhibition helps prevent the recurrence of estrogen-receptor positive breast cancer but also results in cognitive, sleep and thermoregulatory disturbances. These side-effects diminish quality of life and contribute to treatment nonadherence in a large proportion of patients. DHED is a brain-selective prodrug that, in rodent models, converts to 17ฮฒ-estradiol (E2) selectively in the brain without affecting the periphery.
We investigated whether DHED could prevent side effects associated with the aromatase inhibitor letrozole in a primate model of aging. Chronic oral treatment with DHED in letrozole-treated male and female marmosets led to a robust increase in E2ย levels across brain regions without affecting estrogen levels at the periphery.
In addition, DHED treatment (1) improved memory at short delays and prevented letrozole-induced cognitive slowing in a hippocampal-dependent memory task; (2) normalized hippocampal neuronal membrane potential and excitability and (3) reduced sleep fragmentation. However, DHED treatment had opposite effects on thermoregulation in males and females, necessitating additional research in this area.
Overall, the results suggest that DHED, which lacks estrogenic effects in peripheral tissues, could be a safe and effective novel hormonal therapy for improving quality of life in breast cancer patients treated with aromatase inhibitors.
